Assessment cycle 2023 Q1
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Record of documents ratified in the 2023 Q1 assessment cycle.
18 Mar 2023 -
Consultation on the policy governing the declaration and management of interests across the Institute, covering assessment committee members, external reviewers…
01 Apr 2023 -
Consultation on the policy governing what funding the Institute accepts, from whom, and on what published terms. The draft prohibits any funding arrangement that confers…
24 Mar 2023 -
Glucose regulation impaired beyond normal limits but below diagnostic thresholds for diabetes, including impaired fasting glucose, impaired glucose tolerance, and…
16 Mar 2023 -
Degenerative joint disease of the knee with radiographic or symptomatic confirmation, occurring with obesity as a mechanical and inflammatory contributor.
09 Mar 2023 -
Triple GIP, GLP-1 and glucagon receptor agonist (acylated). Retatrutide adds glucagon receptor agonism to the dual incretin mechanism. Glucagon receptor activation increases hepatic fatty-acid oxidation and…
Moderate19 May 2023 -
Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide). Hexarelin is a potent ghrelin receptor agonist producing marked growth-hormone release. Unlike ipamorelin it also stimulates…
Very low10 Mar 2024 -
Synthetic pentadecapeptide derived from a gastric juice protein sequence. The proposed mechanism is angiogenic and cytoprotective action through VEGF receptor 2 transactivation and nitric-oxide-pathway modulation…
Very low11 May 2024 -
C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. KPV inhibits NF-κB activation and reduces pro-inflammatory cytokine production in epithelial and immune cells. Reported uptake through the…
Very low01 Mar 2024 -
Determination of chromatographic purity of synthetic peptides by reverse-phase high-performance liquid chromatography
High01 Oct 2023 -
Confirmation of peptide identity by liquid chromatography–tandem mass spectrometry
High02 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity randomising 1,961 participants over 68 weeks. Primary result: Mean change −14.9 %…
High27 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity and type 2 diabetes randomising 1,210 participants over 68 weeks. Primary result…
High20 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity randomising 611 participants over 68 weeks. Primary result: Mean change −16.0 %…
High17 Aug 2023 -
Randomised withdrawal, phase 3 study of Semaglutide in obesity randomising 803 participants over 48 weeks after a 20-week run-in. Primary result: Continued treatment…
High24 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity and prediabetes randomising 304 participants over 104 weeks. Primary result: Mean…
High13 Sep 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Semaglutide in obesity randomising 338 participants over 68 weeks. Primary result: Mean change −15.8 % with…
High06 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in adolescent obesity randomising 201 participants over 68 weeks. Primary result: Mean change…
Moderate13 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in hfpef and obesity randomising 529 participants over 52 weeks. Primary result: Clinical…
Moderate05 Jul 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide in cardiovascular and obesity randomising 17,604 participants over mean 39.8 months. Primary…
High07 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes randomising 388 participants over 30 weeks. Primary result: Reduction of…
High20 Aug 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes randomising 3,297 participants over 104 weeks. Primary…
High27 Aug 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Semaglutide in type 2 diabetes randomising 1,201 participants over 40 weeks. Primary result: Difference…
High01 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in type 2 diabetes randomising 703 participants over 26 weeks. Primary result…
High19 Jan 2024 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes randomising 3,183 participants over median 15.9…
High24 May 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in obesity randomising 667 participants over 68 weeks. Primary result: Mean change −15.1…
Moderate14 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity randomising 2,539 participants over 72 weeks. Primary result: Mean change −20.9 %…
High15 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity and type 2 diabetes randomising 938 participants over 72 weeks. Primary result…
High02 May 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity randomising 806 participants over 72 weeks after a 12-week lead-in. Primary result…
High24 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 478 participants over 40 weeks. Primary result: Reduction of…
High06 Nov 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 1,879 participants over 40 weeks. Primary result: All three…
High15 Mar 2024 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 1,444 participants over 52 weeks. Primary result: Superior…
High26 Mar 2024 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in type 2 diabetes and cardiovascular randomising 2,002 participants over median 85 weeks…
High20 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 475 participants over 40 weeks. Primary result: Reduction of…
High12 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Retatrutide in obesity randomising 338 participants over 48 weeks. Primary result: Mean change −24.2 % at…
Moderate09 May 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Retatrutide in type 2 diabetes randomising 281 participants over 36 weeks. Primary result: Reduction of up…
Moderate09 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in obesity randomising 272 participants over 36 weeks. Primary result: Mean change up to…
Moderate09 May 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in type 2 diabetes randomising 383 participants over 26 weeks. Primary result: Reduction of…
Moderate12 Sep 2023 -
Randomised, double-blind, active-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity randomising 92 participants over…
Low12 Aug 2023 -
Dose-finding, phase 2 study of Cagrilintide in obesity randomising 706 participants over 26 weeks. Primary result: Dose-dependent change to −10.8 % at 4.5 mg versus −3.0…
Moderate10 Nov 2023
page 1 of 13